These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 24895230)

  • 1. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 5. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
    Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
    Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
    Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
    Petrillo M; Zucchetti M; Cianci S; Morosi L; Ronsini C; Colombo A; D'Incalci M; Scambia G; Fagotti A
    J Gynecol Oncol; 2019 Jul; 30(4):e59. PubMed ID: 31074245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer.
    Marocco F; Vaira M; Milani A; Genta S; Maggiorotto F; Magistris A; Cinquegrana A; Robella M; De Simone M; Aglietta M; Ponzone R; Valabrega G
    Eur J Gynaecol Oncol; 2016; 37(5):638-643. PubMed ID: 29787001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
    Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
    Halkia E; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence.
    Cianci S; Ronsini C; Vizzielli G; Tropea A; Biondi A; Scambia G; Fagotti A
    Updates Surg; 2019 Jun; 71(2):389-394. PubMed ID: 30406932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
    Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
    Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
    Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
    Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.